Santral Nedenli Hipersomnolans
Özet
Pediyatrik popülasyonda yaygın ancak sıklıkla gözden kaçan bir durum olan santral nedenli hipersomnolans, narkolepsi, idiyopatik hipersomni ve Kleine-Levin sendromu gibi çeşitli alt grupları içeren çok faktörlü bir uyku bozukluğudur. ICSD-3 kriterlerine göre sınıflandırılan bu hastalıklar, gündüz aşırı uykululuk hali, katapleksi ve uyku-uyanıklık döngüsündeki bozukluklarla karakterize klinik tablolar sunar. Tanı süreci, detaylı klinik öykünün yanı sıra polisomnografi ve çoklu uyku latansı testi (MSLT) gibi objektif yöntemlerin kullanımını gerektirir. Tedavi yaklaşımları semptomatik olup, hastanın yaşam kalitesini artırmak ve kaza riskini en aza indirmek için bireyselleştirilmiş farmakolojik stratejileri içerir.
Central hypersomnolence is a multifactorial sleep disorder in the pediatric population that often remains unrecognized, encompassing conditions such as narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome. Classified under ICSD-3 criteria, these disorders present with clinical features including excessive daytime sleepiness, cataplexy, and disrupted sleep-wake cycles. Diagnostic evaluation relies on comprehensive clinical history combined with objective assessments like polysomnography and the Multiple Sleep Latency Test (MSLT). Treatment strategies are symptomatic and necessitate individualized pharmacological approaches to improve patient quality of life and minimize accident risks.
Referanslar
Kotagal S. Hypersomnia in children. Sleep Medicine Clinics. 2012;7:379-89.
American Academy of Sleep Medicine. International Classification of Sleep Disorders. Third ed. Darien, IL: American Academy of Sleep Medicine; 2014.
Young TB. Epidemiology of daytime sleepiness: definitions, symptomatology, and prevalence. J Clin Psychiatry. 2004;65(16):12-6.
Leger D, Poursain B, Neubauer D, Uchiyama M. An international survey of sleeping problems in the general population. Curr Med Res Opin. 2008;24:307-17.
Dauvilliers Y, Barateau L. Narcolepsy and Other Central Hypersomnias. Continuum (Minneap Minn). 2017;23(4):989-1004.
Kothare SV, Kaleyias J. The clinical and laboratory assessment of the sleepy child. Seminars in pediatric neurology. 2008;15:61-9.
Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Ouantification of sleepiness: A new approach. Psychophysiology. 1973;10: 431-6.
Johns MW. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep. 1991;14:540-5.
Melendres MC, Lutz JM, Rubin ED, Marcus CL. Daytime sleepiness and hyperactivity in children with suspected sleep-disordered breathing. Pediatrics. 2004;114:768-75.
Drake C, Nickel C, Burduvali E, Roth T, Jefferson C, Pietro B. The paediatric dytime sleepines scale (PDSS): sleep habits and school outcomes in middle-school children. Sleep. 2003;26:455- 8
Meltzer LJ, Montgomery-Downs HE, Insana SP, Walsh CM. Use of Actigraphy for Assessment in Pediatric Sleep Research. Sleep Med Review. 2012;16:463-75.
Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, et al. AASM Scoring Manual Updates for 2017 (Version 2.4). J Clin Sleep Med. 2017;13(5):665-6.
Aurora RN, Lamm CL, Zak RS, Kristo DA, Bista SR, Rowley JA, et al. Practice parameters for the non-respiratory indications for polysomnography and multiple sleep latency testing for children. Sleep. 2012;35:1467-73
Sateia, Michael J. "International classification of sleep disorders." Chest 146.5 (2014): 1387-1394.
Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature medicine. 2000;6:991-7.
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:469-74.
Krahn LE, Pankratz VS, Oliver L, Boeve BF, Silber MH. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep. 2002;25:733-36.
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. The Lancet. 2000;355:39-40.
Mignot E, Hayduk R, Black J, Grumet F, Guilleminault C. HLA DQB1* 0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. 1997;20:1012-20.
Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, Kawashima M, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nature genetics. 2009;41:708-11.
Faraco J, Lin L, Kornum BR, Kenny EE, Trynka G, Einen M, et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS genetics. 2013;9:e1003270.
Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One. 2012 7:e33 536.
Luca G, Haba-Rubio J, Dauvilliers Y, Lammers GJ, Overeem S, Donjacour CE, et al. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. Journal of sleep research. 2013;22:482-95.
Serra L, Montagna P, Mignot E, Lugaresi E, Plazzi G. Cataplexy features in childhood narcolepsy. Movement disorders : official journal of the Movement Disorder Society. 2008;23:858-65.
Plazzi G, Pizza F, Palaia V, Franceschini C, Poli F, Moghadam KK, et al. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain. 2011;134:3480-92.
Pizza F, Franceschini C, Peltola H, Vandi S, Finotti E, Ingravallo F, et al. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain. 2013;136:3787-95.
Houghton WC, Scammell TE, Thorpy M. Pharmacotherapy for cataplexy. Sleep medicine reviews. 2004;8:355-66.
Dauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. Cataplexy--clinical aspects, pathophysiology and management strategy. Nature reviews Neurology. 2014;10:386-95.
Overeem S, Reijntjes R, Huyser W, Jan Lammers G, Gert van Dijk J. Corticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atonia. Journal of sleep research. 2004;13:257-64.
Sturzenegger C, Bassetti CL. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. Journal of sleep research. 2004;13:395-406.
Ohayon MM, Zulley J, Guilleminault C, Smirne S. Prevalence and pathologic associations of sleep paralysis in the general population. Neurology. 1999;52:1194-94.
Ohayon MM, Priest RG, Caulet M, Guilleminault C. Hypnagogic and hypnopompic hallucinations: pathological phenomena? The British Journal of Psychiatry. 1996;169:459-67.
Nishino S, Mao J, Sampathkumaran R, Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep research online: SRO. 1997;1:49- 61.
Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep medicine. 2003;4:579-82.
Aran AE, Mali; Lin, Ling; Plazzi, Guiseppe; Nishino, Seiji; Mignot, Emmanuel. Clinical and Therapeutic Aspects of Childhood Narcolepsy-Cataplexy: A Retrospective Study of 51 Children. Sleep. 2010;33.
Billiard M, Bassetti C, Dauvilliers Y, Dolenc‐Groselj L, Lammers G, Mayer G, et al. EFNS guidelines on management of narcolepsy. European journal of neurology. 2006;13:1035- 48.
Trotti LM. Waking up is the hardest thing I do all day: sleep inertia and sleep drunkenness. Sleep Med Rev 2016. pii:S1087-0792(16)30091-0. doi:10.1016/ j.smrv.2016.08.005.
Rye DB, Bliwise DL, Parker K, et al. Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors. Sci Transl Med 2012;4(161): 161ra151. doi:10.1126/scitranslmed.3004685.
Dauvilliers Y, Evangelista E, Lopez R, et al. Absence of ,-aminobutyric acid-a receptor potentiation in central hypersomnolence disorders. Ann Neurol 2016;80(2):259Y268. doi:10.1002/ana.24710.
Lavault S, Dauvilliers Y, Drouot X, et al. Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Med 2011;12(6):550Y556. doi:10.1016/ j.sleep.2011.03.010.
Mayer G, Benes H, Young P, et al. Modafinil in the treatment of idiopathic hypersomnia without long sleep timeYa randomized, double-blind, placebo-controlled study. J Sleep Res 2015;24(1):74Y81. doi:10.1111/jsr.12201.
Ali M, Auger RR, Slocumb NL, Morgenthaler TI. Idiopathic hypersomnia: clinical features and response to treatment. J Clin Sleep Med 2009;5(6):562Y568.
Afolabi-Brown O, Mason TBA. Kleine-Levin syndrome. Paediatr Respir Rev. 2018;25:9-13.
Lavault S, Golmard JL, Grods E , Groos E, Brion A, Dauvilliers Y, et al. Kleine-Levin syndrome in 120 patients; differential diagnosis and long episodes. Ann Neurol. 2015;77:529-40.
Arnulf I, Rico TJ, Mignot E. Diagnosis, disease course, and management of patients with Kleine-Levin syndrome. Lancet Neurol 2012;11(10):918Y928. doi:10.1016/ S1474-4422(12)70187-4.
Dauvilliers Y, Baumann CR, Carlander B, et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003;74(12): 1667Y1673. doi:10.1136/jnnp.74.12.1667.
Leu-Semenescu S, Le Corvec T, Groos E, et al. Lithium therapy in Kleine-Levin syndrome: an open-label, controlled study in 130 patients. Neurology 2015; 85(19):1655Y1662. doi:10.1212/ WNL.0000000000002104.
Mathias JL, Alvaro PK. Prevalence of sleep disturbances, disorders, and problems following traumatic brain injury: a meta-analysis. Sleep medicine. 2012;13:898-905.
Watson NF, Dikmen S, Machamer J, Doherty M, Temkin N. Hypersomnia following traumatic brain injury. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2007;3:363-8.
Tham SW, Palermo TM, Vavilala MS, Wang J, Jaffe KM, Koepsell TD, et al. The longitudinal course, risk factors, and impact of sleep disturbances in children with traumatic brain injury. Journal of neurotrauma. 2012;29:154-61.
Verberne LM, Maurice-Stam H, Grootenhuis MA, Van Santen HM, Schouten-Van Meeteren AY. Sleep disorders in children after treatment for a CNS tumour. Journal of sleep research. 2012;21:461-9.
Powell C, Guerrero D, Sardell S, Cumins S, Wharram B, Traish D, et al. Somnolence syndrome in patients receiving radical radiotherapy for primary brain tumours: a prospective study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011;100:131-6.
Manni R, Politini L, Nobili L, Ferrillo F, Livieri C, Veneselli E, et al. Hypersomnia in the Prader Willi syndrome: clinical-electrophysiological features and underlying factors. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2001;112:800-5.
Bruni O, Verrillo E, Novelli L, Ferri R. Prader-Willi syndrome: sorting out the relationships between obesity, hypersomnia, and sleep apnea. Current opinion in pulmonary medicine. 2010;16:568-73.
Nevsimalova S, Vankova J, Stepanova I, Seemanova E, Mignot E, Nishino S. Hypocretin deficiency in Prader-Willi syndrome. European journal of neurology : the official journal of the European Federation of Neurological Societies. 2005;12:70-2.
De Cock VC, Diene G, Molinas C, Masson VD, Kieffer I, Mimoun E, et al. Efficacy of modafinil on excessive daytime sleepiness in Prader-Willi syndrome. American journal of medical genetics Part A. 2011;155A:1552-7.
Dauvilliers YA, Laberge L. Myotonic dystrophy type 1, daytime sleepiness and REM sleep dysregulation. Sleep medicine reviews. 2012;16:539-45.
Puymirat J, Bouchard JP, Mathieu J. Efficacy and tolerability of a 20-mg dose of methylphenidate for the treatment of daytime sleepiness in adult patients with myotonic dystrophy type 1: a 2-center, randomized, double-blind, placebo-controlled, 3-week crossover trial. Clinical therapeutics. 2012;34:1103-11.
Gropman AL, Duncan WC, Smith ACM. Neurologic and Developmental Features of the Smith-Magenis Syndrome (del 17p11.2). Pediatric neurology. 2006;34:337-50.
De Leersnyder H, Bresson JL, de Blois M-C, Souberbielle J-C, Mogenet A, Delhotal-Landes B, et al. β1-adrenergic antagonists and melatonin reset the clock and restore sleep in a circadian disorder, Smith-Magenis syndrome. Journal of Medical Genetics. 2003;40:74-78.
Vanier MT. Niemann-Pick disease type C. Orphanet journal of rare diseases. 2010;5:16.
Nevsimalova S, Malinova V. Cataplexy and sleep disorders in Niemann-Pick type C disease. Current neurology and neuroscience reports. 2015;15:522.
Ward CD. On doing nothing: descriptions of sleep, fatigue, and motivation in encephalitis lethargica. Movement disorders : official journal of the Movement Disorder Society. 2011;26:599-604.
Dauvilliers Y, Lopez R, Ohayon M, Bayard S. Hypersomnia and depressive symptoms: methodological and clinical aspects. BMC Med 2013;11:78. doi:10.1186/ 1741-7015-11-78.
